- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06808477
Une étude de BBT001 chez des volontaires sains (HVS) et chez des patients adultes atteints de dermatite atopique (AD)
Une étude de dose randomisée, aveugle et contrôlée par placebo, pour évaluer la sécurité, la tolérabilité, la pharmacocinétique, l'immunogénicité, la pharmacodynamique et l'activité clinique de BBT001 chez les patients HV et les patients AD
This is a Phase 1, randomized, blinded, placebo controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This study a is a randomized, double-blinded, placebo-controlled single (SAD) and multiple-ascending dose (MAD) study to evaluate safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics, and exploratory clinical activity of BBT001 in healthy volunteers (HVs) and in adult patients with atopic dermatitis. BBT001 is a drug candidate being developed for the treatment of atopic dermatitis.
Type d'étude
Inscription (Estimé)
Phase
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Lisa Li
- Numéro de téléphone: +1 617-848-6188
- E-mail: Lisa.Li@bambusatx.com
Lieux d'étude
-
-
Western Australia
-
Fremantle, Western Australia, Australie, 6160
- Recrutement
- Fremantle Dermatology
-
Perth, Western Australia, Australie, 6009
- Complété
- Linear Clinical Research
-
-
-
-
-
Christchurch, Nouvelle-Zélande
- Recrutement
- Optimal Clinical Trials Ltd - Christchurch
-
Upper Hutt, Nouvelle-Zélande, 5018
- Recrutement
- Pacific Clinical Research Network (PCRN) Wellington
-
Contact:
- Tim Humphrey
-
-
Auckland
-
Grafton, Auckland, Nouvelle-Zélande, 1010
- Recrutement
- Optimal Clinical Trials Central Auckland
-
Contact:
- Arna Letica
-
Otahuhu, Auckland, Nouvelle-Zélande, 2025
- Retiré
- Aotearoa Clinical Trials
-
Takapuna, Auckland, Nouvelle-Zélande, 0622
- Recrutement
- Pacific Clinical Research Network (PCRN) - Auckland
-
Contact:
- Paul Hamilton
-
-
-
-
-
Lodz, Pologne, 91-347
- Recrutement
- Wojewódzki Specjalistyczny Szpital im. Dr. Wł. Biegańskiego w Łodzi
-
Rzeszów, Pologne, 35-055
- Recrutement
- Uniwersytecki Szpital Kliniczny im. Fryderyka Chopina w Rzeszowie
-
Warsaw, Pologne, 02-507
- Recrutement
- Państwowy Instytut Medyczny MSWiA
-
Wroclaw, Pologne, 50-566
- Recrutement
- Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak Spółka Partnerska
-
-
-
-
California
-
Irvine, California, États-Unis, 92614
- Recrutement
- First OC Dermatology
-
-
New York
-
New York, New York, États-Unis, 10128
- Recrutement
- OptiSkin Medical
-
The Bronx, New York, États-Unis, 10455
- Recrutement
- Equity Medical, LLC
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Key Inclusion Criteria
- Negative pregnancy tests for women of childbearing potential.
- Willingness to refrain from alcohol consumption for 24 hours prior to each study visit.
- Non-smokers, healthy current smokers (≤5 cigarettes/day), or ex-smokers.
- Adequate contraception use (for men and women of childbearing potential).
Key Inclusion Criteria (Parts A, B, and D)
- Age of 18-65 years.
- Body mass index of 18 to 32 kg/m², weight capped at 120 kg.
- No clinically significant abnormalities or history of relevant diseases.
Key Inclusion Criteria (Parts C and E only)
- Age of 18-72 years.
- Body mass index ≥16 kg/m², weight capped at 125 kg.
- Must have dermatologist-confirmed chronic atopic dermatitis (≥12 months). Inadequate response to topical treatments or where they are medically inadvisable.
- Moderate to severe atopic dermatitis
- Validated investigator's global assessment for atopic dermatitis (vIGA-ADTM) score ≥3
- Atopic lesions cover ≥10% of body surface area (BSA)
- Average peak pruritus numeric rating scale (PP-NRS) score ≥4 in the 7 days before randomization.
Key Exclusion Criteria
- Significant health issues, such as: diabetes, positive tests for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B surface antigen (HBsAg), immunodeficiencies, autoimmune diseases, or cancer, history of conditions predisposing to infections.
- History of major metabolic, dermatological, liver, kidney, hematological, or other significant disorders.
- Clinically relevant abnormal lab results, including low blood counts, liver issues, or abnormal kidney function.
- Positive drug/alcohol tests or abnormal vital signs at screening or Day -1.
- Abnormal Electrocardiogram (ECG) findings
- History of drug/alcohol abuse in the past 2 years.
- Donated >500mL blood within 2 months of screening.
- History of severe allergic reactions or hypersensitivity.
Key Exclusion Criteria (Parts A, B, and D only)
1. History of atopic dermatitis
Key Exclusion Criteria (Parts C and E only)
- Skin diseases other than atopic dermatitis, significant tattoos, or scarring.
- Receipt of immunoglobulin or blood products within 30 days.
- Atopic dermatitis with ocular symptoms or chronic ocular steroid use.
- Chronic pruritus from conditions other than atopic dermatitis.
- Acute/treated infections or chronic skin infections.
- Current use of sedating antihistamines or corticosteroids.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Part A Single Ascending Dose BBT001
A single dose of BBT001 will be administered in healthy volunteers |
BBT001 will be administered |
|
Expérimental: Part B Multiple Ascending Dose BBT001
Multiple doses of BBT001 will be administered in healthy volunteers. |
BBT001 will be administered |
|
Expérimental: Part C Multiple Ascending Dose BBT001
Multiple doses of BBT001 will be administered in patients with atopic dermatitis. |
BBT001 will be administered |
|
Comparateur placebo: Part A Single Ascending Dose Placebo
A single dose of Placebo will be administered in healthy volunteers |
Placebo will be administered |
|
Comparateur placebo: Part B Multiple Ascending Dose Placebo
Multiple doses of Placebo will be administered in healthy volunteers. |
Placebo will be administered |
|
Comparateur placebo: Part C Multiple Ascending Dose Placebo
Multiple doses of Placebo will be administered in patients with atopic dermatitis. |
Placebo will be administered |
|
Comparateur actif: Part D Single Ascending Dose BBT001
A single dose of BBT001 will be administered in healthy volunteers |
BBT001 will be administered |
|
Comparateur placebo: Part D Single Ascending Dose Placebo
A single dose of placebo will be administered in healthy volunteers |
Placebo will be administered |
|
Comparateur actif: Part E Multiple Ascending Dose BBT001 - Dose Level 1
Multiple doses of BBT001 will be administered in patients with atopic dermatitis. |
BBT001 will be administered |
|
Comparateur placebo: Part E Multiple Ascending Dose Placebo
Multiple doses of placebo will be administered in patients with atopic dermatitis. |
Placebo will be administered |
|
Comparateur actif: Part E Multiple Ascending Dose BBT001 - Dose Level 2
Multiple doses of BBT001 will be administered in patients with atopic dermatitis |
BBT001 will be administered |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of participants with adverse events following single and multiple administration of BBT001
Délai: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
Incidence, relatedness, and severity of adverse events graded per NCI CTCAE v5.0. |
Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
|
Number of participants with change in serum blood parameters
Délai: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
Laboratory assessments include hematology, blood chemistry and coagulation test |
Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
|
Number of participants with change in vital sign measurements following treatment administration.
Délai: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
Blood pressure and heart rate will be assessed. |
Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
|
Number of participants with change in physical examination following treatment administration.
Délai: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
Physical examination will be assessed. |
Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
|
Number of participants with change in 12-lead ECG readings
Délai: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
12-lead ECG will be assessed. |
Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Pharmacokinetics parameters - maximum observed Concentration (Cmax)
Délai: At specified timepoints pre-dose and up to 169 days post first dose administration
|
Maximum observed concentration of the study drug in serum will be analyzed for all subjects |
At specified timepoints pre-dose and up to 169 days post first dose administration
|
|
Pharmacokinetics parameters - Time for maximum observed Concentration (Tmax)
Délai: At specified timepoints pre-dose and up to 169 days post first dose administration
|
Serum PK Tmax will be analyzed for all subjects |
At specified timepoints pre-dose and up to 169 days post first dose administration
|
|
Pharmacokinetics parameters - Area under the curve (AUC)
Délai: At specified timepoints pre-dose and up to 169 days post first dose administration
|
Area under the curve of the study drug in serum will be analyzed for all subjects |
At specified timepoints pre-dose and up to 169 days post first dose administration
|
|
Pharmacokinetics parameters - Volume of distribution (Vz)
Délai: At specified timepoints pre-dose and up to 169 days post first dose administration
|
Volume of distribution of the study drug in serum will be analyzed for all subjects |
At specified timepoints pre-dose and up to 169 days post first dose administration
|
|
Pharmacokinetics parameters - Total clearance (CL)
Délai: At specified timepoints pre-dose and up to 169 days post first dose administration
|
Total clearance of the study drug in serum will be analyzed for all subjects |
At specified timepoints pre-dose and up to 169 days post first dose administration
|
|
Pharmacokinetics parameters - Elimination Half-life (t1/2).
Délai: At specified timepoints pre-dose and up to 169 days post first dose administration
|
Elimination half-life of the study drug in serum will be analyzed for all subjects |
At specified timepoints pre-dose and up to 169 days post first dose administration
|
|
The immunogenicity of BBT001 is measured as the number and percentage of subjects who develop Anti-Drug Antibodies (ADA).
Délai: At specified timepoints pre-dose and up to 169 days post first dose administration
|
Serum Anti-Drug Antibodies will be analyzed for all subjects |
At specified timepoints pre-dose and up to 169 days post first dose administration
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Lisa Li, Bambusa Therapeutics, Inc.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies génétiques, innées
- Maladies du système immunitaire
- Hypersensibilité immédiate
- Hypersensibilité
- Maladies de la peau
- Maladies de la peau, Génétique
- Maladies de la peau, eczémateux
- Dermatite
- Maladies et anomalies congénitales, héréditaires et néonatales
- Maladies de la peau et du tissu conjonctif
- Dermatite atopique
Autres numéros d'identification d'étude
- BBT001-001
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .